Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands, and Specialty Generics and Amitiza. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone44-0-17-8463-6700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.22 billion
Profitability
Miscellaneous
Employees3,700
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable
Mallinckrodt (NYSE:MNK) Frequently Asked Questions
What is Mallinckrodt's stock symbol?
Mallinckrodt trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK."
How were Mallinckrodt's earnings last quarter?
Mallinckrodt PLC (NYSE:MNK) announced its quarterly earnings data on Tuesday, November, 5th. The company reported $2.07 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.98 by $0.09. The company earned $743.70 million during the quarter, compared to analyst estimates of $770.56 million. Mallinckrodt had a negative net margin of 111.44% and a positive return on equity of 24.36%. The firm's revenue for the quarter was down 7.0% compared to the same quarter last year. During the same period last year, the business earned $2.10 EPS. View Mallinckrodt's Earnings History.
When is Mallinckrodt's next earnings date?
What price target have analysts set for MNK?
14 Wall Street analysts have issued 12 month price targets for Mallinckrodt's stock. Their forecasts range from $2.00 to $22.00. On average, they expect Mallinckrodt's share price to reach $8.64 in the next year. This suggests a possible upside of 67.2% from the stock's current price. View Analyst Price Targets for Mallinckrodt.
What is the consensus analysts' recommendation for Mallinckrodt?
14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mallinckrodt in the last year. There are currently 1 sell rating, 10 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Mallinckrodt.
Has Mallinckrodt been receiving favorable news coverage?
Press coverage about MNK stock has been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Mallinckrodt earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Mallinckrodt.
Are investors shorting Mallinckrodt?
Mallinckrodt saw a decline in short interest during the month of December. As of December 13th, there was short interest totalling 46,160,000 shares, a decline of 9.4% from the November 28th total of 50,930,000 shares. Based on an average trading volume of 7,250,000 shares, the days-to-cover ratio is currently 6.4 days. Approximately 55.7% of the company's shares are short sold. View Mallinckrodt's Current Options Chain.
Who are some of Mallinckrodt's key competitors?
Some companies that are related to Mallinckrodt include Akcea Therapeutics (AKCA), Tricida (TCDA), Arvinas (ARVN), Forty Seven (FTSV), Alder Biopharmaceuticals (ALDR), Ligand Pharmaceuticals (LGND), Constellation Pharmaceuticals (CNST), Corcept Therapeutics (CORT), Theravance Biopharma (TBPH), Innoviva (INVA), Amneal Pharmaceuticals (AMRX), BELLUS Health (BLUSF), Y-mAbs Therapeutics (YMAB), TG Therapeutics (TGTX) and Endo International (ENDP).
What other stocks do shareholders of Mallinckrodt own?
Who are Mallinckrodt's key executives?
Mallinckrodt's management team includes the folowing people:
- Mr. Mark Christopher Trudeau, Pres, CEO & Director (Age 58)
- Dr. Frank Scholz, Exec. VP and Chief Operations & Digital Innovation Officer (Age 50)
- Mr. Matthew K. Harbaugh, Exec. VP & Pres of Specialty Generics (Age 49)
- Mr. Hugh M. O'Neill, Exec. VP & Chief Commercial Officer (Age 56)
- Mr. Bryan M. Reasons, Chief Financial Officer (Age 52)
Who are Mallinckrodt's major shareholders?
Mallinckrodt's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Strs Ohio (0.20%), Eqis Capital Management Inc. (0.15%), Clear Creek Financial Management LLC (0.03%), Beirne Wealth Consulting Services LLC (0.03%) and Commerzbank Aktiengesellschaft FI (0.02%). Company insiders that own Mallinckrodt stock include Bryan M Reasons, James E Flynn and Mark Trudeau. View Institutional Ownership Trends for Mallinckrodt.
Which institutional investors are selling Mallinckrodt stock?
MNK stock was sold by a variety of institutional investors in the last quarter, including Commerzbank Aktiengesellschaft FI, Strs Ohio, Eqis Capital Management Inc. and Clear Creek Financial Management LLC. View Insider Buying and Selling for Mallinckrodt.
Which institutional investors are buying Mallinckrodt stock?
MNK stock was bought by a variety of institutional investors in the last quarter, including Beirne Wealth Consulting Services LLC. Company insiders that have bought Mallinckrodt stock in the last two years include Bryan M Reasons and Mark Trudeau. View Insider Buying and Selling for Mallinckrodt.
How do I buy shares of Mallinckrodt?
Shares of MNK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Mallinckrodt's stock price today?
One share of MNK stock can currently be purchased for approximately $5.17.
How big of a company is Mallinckrodt?
Mallinckrodt has a market capitalization of $434.75 million and generates $3.22 billion in revenue each year. The company earns $-3,607,000,000.00 in net income (profit) each year or $8.01 on an earnings per share basis. Mallinckrodt employs 3,700 workers across the globe.View Additional Information About Mallinckrodt.
What is Mallinckrodt's official website?
How can I contact Mallinckrodt?
Mallinckrodt's mailing address is 3 LOTUS PARK THE CAUSEWAY STAINES-UPON-THAMES, SURREY X0, TW18 3AG. The company can be reached via phone at 44-0-17-8463-6700 or via email at [email protected]
MarketBeat Community Rating for Mallinckrodt (NYSE MNK)
MarketBeat's community ratings are surveys of what our community members think about Mallinckrodt and other stocks. Vote "Outperform" if you believe MNK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNK will underperform the S&P 500 over the long term. You may vote once every thirty days.
